Back
ESC Premium Access

Real-world comparison of major bleeding risk associated with direct oral anticoagulants or warfarin in patients with non-valvular atrial fibrillation: a systematic review and network meta-analysis.

Session: Poster session 3 - Drug treatment
Topic: Antiarrhythmic drugs
Speaker: Doctor S. Deitelzweig (New Orleans, US)
Event: ESC Congress 2017

Congress Presentation

About the speaker

Doctor Steven Deitelzweig

Ochsner Medical Center, New Orleans (United States of America)
7 presentations
0 follower

24 more presentations in this session

Impact of digoxin use on adverse outcomes in patients with atrial fibrillation: results from a multicenter atrial fibrillation registry study in China

Speaker: Miss S. Wu (Beijing, CN)

Access
Abstract
Slides
Thumbnail

Rate-control treatment and clinical outcomes in patients with atrial fibrillation and obstructive lung disease

Speaker: Doctor S. You (Seoul, KR)

Access
Abstract
Slides
Thumbnail

Efficacy of acute intravenous therapy with potassium, magnesium and metoprolol in recent-onset atrial fibrillation

Speaker: Miss A. Moser (Hamburg, DE)

Access
Abstract
Thumbnail

Postoperative atrial fibrillation in patients with reduced ejection fraction heart failure undergoing cardiac surgery: ranolazine shortens time to conversion when added to amiodarone

Speaker: Professor J. Skoularigis (Larissa, GR)

Access
Abstract
Slides
Thumbnail

INR prior to bleeding is below 3.0 most of the time in patients with atrial fibrillation using warfarin

Speaker: Doctor P. Oliveira Guimaraes (Durham, US)

Access
Abstract
Slides
Thumbnail

Access the full session

Poster session 3 - Drug treatment

Speakers: Doctor S. Deitelzweig, Miss S. Wu, Doctor S. You, Miss A. Moser, Professor J. Skoularigis...
Access
Thumbnail

About the event

Image

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb